Advertisement
Screener

RAFAEL HOLDINGS, INC. (RFL) Proceeds from Notes Payable

2.8 / 5 stars · 68/120 Roast Me

RAFAEL HOLDINGS, INC. Proceeds from Notes Payable

RAFAEL HOLDINGS, INC. (RFL) reported Proceeds from Notes Payable of $10.00 billion for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-11.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromNotesPayable · last filed 2026-06-11

  • RAFAEL HOLDINGS, INC. proceeds from notes payable for the quarter ending 2026-04-30 was $0.00.
  • RAFAEL HOLDINGS, INC. proceeds from notes payable for the quarter ending 2026-01-31 was $0.00, a 100.00% decline year-over-year.
  • RAFAEL HOLDINGS, INC. proceeds from notes payable for the quarter ending 2025-10-31 was $10.00B, a 99900.00% increase year-over-year.
  • RAFAEL HOLDINGS, INC. proceeds from notes payable for the quarter ending 2025-07-31 was $0.00.
  • RAFAEL HOLDINGS, INC. proceeds from notes payable for fiscal 2025 was $10.00B, a 99900.00% increase from fiscal 2024.
  • RAFAEL HOLDINGS, INC. proceeds from notes payable for fiscal 2024 was $10.00M.
  • RAFAEL HOLDINGS, INC. proceeds from notes payable for fiscal 2021 was $15.00M.
Period endProceeds from Notes Payable 3 monthProceeds from Notes Payable 6 monthProceeds from Notes Payable 9 monthProceeds from Notes Payable 12 month
2026-04-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11
$0.00
derived: sum of 2 quarters · filed 2026-06-11
$10.00B
10-Q · filed 2026-06-11
$10.00B
derived: sum of 4 quarters · filed 2026-06-11
2026-01-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16
$10.00B
10-Q · filed 2026-03-16
$10.00B
derived: sum of 3 quarters · filed 2026-03-16
$10.00B
derived: sum of 4 quarters · filed 2026-03-16
2025-10-31$10.00B
10-Q · filed 2025-12-12
$10.00B
derived: sum of 2 quarters · filed 2025-12-12
$10.00B
derived: sum of 3 quarters · filed 2025-12-12
$19.99B
derived: sum of 4 quarters · filed 2025-12-12
2025-07-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29
$0.00
derived: sum of 2 quarters · filed 2025-10-29
$9.99B
derived: sum of 3 quarters · filed 2025-10-29
$10.00B
10-K · filed 2025-10-29
2025-04-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11
$9.99B
derived: sum of 2 quarters · filed 2025-06-11
$10.00B
10-Q · filed 2025-06-11
$10.00B
derived: sum of 4 quarters · filed 2025-06-11
2025-01-31$9.99B
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14
$10.00B
10-Q · filed 2025-03-14
$10.00B
derived: sum of 3 quarters · filed 2025-03-14
2024-10-31$10.00M
10-Q · filed 2024-12-11
$10.00M
derived: sum of 2 quarters · filed 2024-12-20
2024-07-31$0.00
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20
$10.00M
10-K/A · filed 2024-12-20
2024-04-30$10.00M
10-Q · filed 2024-06-14
2021-07-31$15.00M
10-K · filed 2021-10-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aditxt, Inc. (ADTX)United States$0.000B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Protagenic Therapeutics, Inc.\new (PTIX)United States$0.001B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B